Cabergoline for non-functioning pituitary adenomas: an update on an old clinical controversy

Cabergoline has been used off-label for non-functioning pituitary adenomas (NFPAs) for decades, yet its place in management remains controversial. We reappraised the evidence, emphasizing studies from the last 3-5 years and how contemporary natural-history data influence interpretation of radiological outcomes.

We conducted a focused PubMed/MEDLINE search from database inception through 27 September 2026, prioritizing comparative studies, recent cohorts, systematic reviews, natural-history studies, translational research, and clinically relevant safety data. Evidence was synthesized narratively.

Earlier studies suggested radiological activity, but the only randomized open-label trial showed primarily a radiological signal, with less growth and more shrinkage, rather than established patient-centered clinical benefit. A 2022 meta-analysis estimated at least 20% shrinkage in 19% and an outcome classified as prevention of progression in 50%. Recent data remain inconsistent: a 2022 multicenter comparison found no clear radiological advantage over observation, a 2024 surgery-naive cohort reported shrinkage/stability/growth in 20%/48%/32%, and 2026 real-world and radiotherapy cohorts have not resolved comparative efficacy. Contemporary natural-history studies show that untreated NFPAs may remain stable, regress, or grow unpredictably. No validated molecular or pathological predictor of cabergoline response has emerged.

Recent evidence adds context but does not resolve this long-standing controversy or support routine cabergoline therapy for NFPAs. Cabergoline remains off-label and has no established routine role; it should not displace established surveillance, neurosurgical, or radiotherapy strategies. Prospective controlled studies using standardized volumetric imaging and patient-centered outcomes are needed.